These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35845967)

  • 1. Association Between Interorganizational Collaboration in Opioid Response and Treatment Capacity for Opioid Use Disorder in Counties of Five States: A Cross-Sectional Study.
    Swann WL; DiNardi M; Schreiber TL
    Subst Abuse; 2022; 16():11782218221111949. PubMed ID: 35845967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Rural vs Urban Direct-to-Physician Commercial Promotion of Medications for Treating Opioid Use Disorder.
    Nguyen T; Andraka-Christou B; Simon K; Bradford WD
    JAMA Netw Open; 2019 Dec; 2(12):e1916520. PubMed ID: 31790568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urban-Rural Disparities in Opioid Use Disorder Prevention and Response Activities: A Cross-Sectional Analysis.
    Swann WL; Kim S; Kim SY; Schreiber TL
    J Rural Health; 2021 Jan; 37(1):16-22. PubMed ID: 32639664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are Rural Opioid Treatment Program (OTP) Facilities Associated with Lower Deaths?
    Meadowcroft D; Whitacre B
    Subst Use Misuse; 2020; 55(5):828-838. PubMed ID: 31856628
    [No Abstract]   [Full Text] [Related]  

  • 7. Access to treatment before and after Medicare coverage of opioid treatment programs.
    Liu R; Beetham T; Newton H; Busch SH
    Health Aff Sch; 2024 Jun; 2(6):qxae076. PubMed ID: 38938273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review.
    Risby J; Schlesinger E; Geminn W; Cernasev A
    Pharmacy (Basel); 2023 Aug; 11(5):. PubMed ID: 37736904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.
    Ghertner R
    Drug Alcohol Depend; 2019 Nov; 204():107527. PubMed ID: 31525570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018.
    Conway KP; Khoury D; Hilscher R; Aldridge AP; Parker SJ; Zarkin GA
    Addict Sci Clin Pract; 2022 Jan; 17(1):5. PubMed ID: 35101112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the opioid use disorder medication treatment workforce in rural communities through the RCORP initiative.
    Andrilla CHA; Woolcock SC; Meyers K; Patterson DG
    J Rural Health; 2024 Jul; ():. PubMed ID: 39054690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Among County-Level Economic Factors, Clinician Supply, Metropolitan or Rural Location, and Neonatal Abstinence Syndrome.
    Patrick SW; Faherty LJ; Dick AW; Scott TA; Dudley J; Stein BD
    JAMA; 2019 Jan; 321(4):385-393. PubMed ID: 30694320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
    Andrilla CHA; Moore TE; Patterson DG; Larson EH
    J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis.
    Amiri S; McDonell MG; Denney JT; Buchwald D; Amram O
    Value Health; 2021 Feb; 24(2):188-195. PubMed ID: 33518025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule.
    Laks J; Kehoe J; Farrell NM; Komaromy M; Kolodziej J; Walley AY; Taylor JL
    Addict Sci Clin Pract; 2021 Dec; 16(1):73. PubMed ID: 34961554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
    Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pronounced Regional Disparities in United States Methadone Distribution.
    Furst JA; Mynarski NJ; McCall KL; Piper BJ
    Ann Pharmacother; 2022 Mar; 56(3):271-279. PubMed ID: 34184584
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.